Bristol-Myers Squibb ( BMY)

Drug: ipilimumab

Abstract No. 4

Indication: melanoma

Clinical Trial: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Presentation Time:Sunday, June 6. ASCO Plenary Session.

Notes:Bristol gained full ownership of ipilimumab when it acquired Medarex in 2009. ASCO did not release the research abstract Thursday night.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today